Abstract
Classical xanthinuria is a rare inherited metabolic disorder caused by either isolated xanthine dehydrogenase (XDH) deficiency (type I) or combined XDH and aldehyde oxidase (AO) deficiency (type II). XDH and AO are evolutionary related enzymes that share a sulfurated molybdopterin cofactor. While the role of XDH in purine metabolism is well established, the physiologic functions of AO are mostly unknown. XDH and AO are important drug metabolizing enzymes. Urine metabolomic analysis by high pressure liquid chromatography and mass spectrometry of xanthinuric patients was performed to unveil physiologic functions of XDH and AO and provide biomarkers for typing xanthinuria. Novel endogenous products of AO, hydantoin propionic acid, N1-methyl-8-oxoguanine and N-(3-acetamidopropyl) pyrrolidin-2-one formed in the histidine, nucleic acid and spermidine metabolic pathways, respectively, were identified as being lowered in type II xanthinuria. Also lowered were the known AO products, N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-5-carboxamide in the nicotinamide degradation pathway. In contrast to the KEGG annotations, the results suggest minor role of human AO in the conversion of pyridoxal to pyridoxate and gentisaldehyde to gentisate in the vitamin B6 and tyrosine metabolic pathways, respectively. The perturbations in purine degradation due to XDH deficiency radiated further from the previously known metabolites, uric acid, xanthine and hypoxanthine to guanine, methyl guanine, xanthosine and inosine. Possible pathophysiological implications of the observed metabolic perturbations are discussed. The identified biomarkers have the potential to replace the allopurinol-loading test used in the past to type xanthinuria, thus facilitating appropriate pharmacogenetic counseling and gene directed search for causative mutations.
Similar content being viewed by others
Abbreviations
- XDH:
-
Xanthine dehydrogenase
- XO:
-
Xanthine oxidase
- HMCS:
-
Human molybdenum cofactor sulfurase
- MS2 :
-
Tandem mass spectra
- KEGG:
-
Kyoto encyclopedia of genes and genomes
- 2PY:
-
N1-methyl-2-pyridone-5-carboxamide
- 4PY:
-
N1-methyl-4-pyridone-5-carboxamide
- NMN:
-
N1-methylnicotinamide
- HPA:
-
Hydantoin propionic acid
- NMOG:
-
N-methyl-8-oxoguanine
- APP:
-
N-(3-acetamidopropyl) pyrrolidin-2-one
- ADH:
-
Aldehyde dehydrogenase
- TPMT:
-
Thiopurine methyl transferase
- 6-MP:
-
6-Mercaptopurine
References
Abelson, D., Boyle, A., & Seligson, H. (1963). Identification of N′-methyl-4-pyridone-3-carboxamide in human plasma. Journal of Biological Chemistry, 238, 717–718.
Ayvazian, J. H., & Skupp, S. (1965). The study of purine utilization and excretion in a xanthinuric man. Journal of Clinical Investigation, 44, 1248–1260.
Cheung, K. J., Tzameli, E., Pissios, P., et al. (2007). Xanthine oxidoreductase is a regulator of adipogenesis and PPARγ activity. Cell Metabolism, 5, 115–128.
Chlopicki, S., Swies, J., Mogielnicki, A., et al. (2007). 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, excerts anti-thrombotic activity mediated by cyclooxygenase-2/prostacyclin pathway. British Journal of Pharmacology, 152, 230–239.
Delaney, J., Hodson, M. P., Thakkar, H., et al. (2005). Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Archives of Toxicology, 79, 208–223.
Gordon, A. H., Green, D. E., & Subrahmanyan, V. (1940). Liver aldehyde oxidase. Biochemical Journal, 34, 764–774.
Hassall, H., & Greenberg, D. M. (1963). The oxidation of 4(5)-imidazolone-5(4)-propionic acid to hydantoin-5-propionic acid by xanthine oxidase. Biochimica et Biophysica Acta, 67, 507–510.
Helbock, H. J., Thompson, J., Yeo, H., & Ames, B. N. (1996). N2-methyl-8-oxoguanine: A tRNA urinary metabolite-role of xanthine oxidase. Free Radical Biology and Medicine, 20, 475–481.
Hille, R., Nishino, T., & Bittner, F. (2011). Molybdenum enzymes in higher organisms. Coordination Chemistry Reviews, 255, 1179–1205.
Hou, Y. M., & Perona, J. P. (2010). Stereochemical mechanisms of t-RNA methyltransferases. FEBS Letters, 584, 278–286.
Ichida, K., Yoshida, M., Sakuma, R., & Hosoya, T. (1998). Two siblings with classical xanthinuria type I: significance of allopurinol loading test. Internal Medicine, 37, 77–82.
Kamleh, M. A., Hobani, Y., Dow, J. A. T., Zheng, L., & Watson, D. G. (2009). Towards a platform for the metabonomic profiling of different strains of Drosophila melanogaster using liquid chromatography-Fourier transform mass spectrometry. FEBS Journal, 276, 6798–6809.
Kitamura, S., Sugihara, K., & Ohta, S. (2006). Drug-metabolizing ability of molybdenum hydroxylases. Drug Metabolism and Pharmacokinetics, 21, 83–98.
Laurence, A., Edbury, S. M., Marinaki, A. M., et al. (2007). 4-pyridone-3-carboxamide ribonucleoside triphosphate accumulating in erythrocytes in end stage renal failure originates from tryptophan metabolism. Clinical and Experimental Medicine, 7, 135–141.
Levartovsky, D., Lagziel, A., Sperling, O., et al. (2000). XDH gene mutation is the underlying cause of classical xanthinuria: A second report. Kidney International, 57, 2215–2220.
Marchitti, S. A., Brocker, C., Stagos, D., & Vasiliou, V. (2008). Non-P450 aldehyde oxidizing enzymes: The aldehyde dehydrogenase superfamily. Expert Opinion on Drug Metabolism and Toxicology, 4, 697–720.
Merrill, A. H., Jr., Henderson, J. M., Wang, E., McDonald, B. W., & Millikan, W. J. (1984). Metabolism of vitamin B-6 by human liver. Journal of Nutrition, 114, 1664–1674.
Ohtsubo, T., Matsumura, K., Sakagami, K., et al. (2009). Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules. Hypertension, 54, 868–876.
Ohtsubo, T., Rovira, I. I., Starost, M. F., Liu, C., & Finkel, T. (2004). Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circulation Research, 95, 1118–1124.
Payes, B., & Greenberg, D. M. (1968). Studies on the enzymatic decomposition of urocanic acid. VII. Identification of the enzyme catalyzing the oxidation of 4(5)-imidazolone-5(4)-propionic acid as an aldehyde oxidase. Archives of Biochemistry and Biophysics, 125, 911–917.
Pegg, A. E., & Casero, R. A., Jr. (2011). Current status of the polyamine research field. In A. E. Pegg & R. A. Casero Jr. (Eds.), Polyamines: methods and protocols, Methods Mol Biol (vol 720) (pp. 3–35). Berlin: Springer Science + Business Media, LLC.
Peretz, H., Shtauber-Naamati, M., Levartovsky, D., et al. (2007). Identification and characterization of the first mutation (Arg776Cys) in the C-terminal domain of the Human Molybdenum Cofactor Sulfurase (HMCS) associated with type II classical xanthinuria. Molecular Genetics and Metabolism, 91, 23–29.
Pryde, D. C., Davie, D., Hu, Q., Jones, P., Obach, R. S., & Tran, T.-D. (2010). Aldehyde oxidase: An enzyme of emerging importance in drug discovery. Journal of Medicinal Chemistry, 53, 8441–8460.
Raison, J. K., Henson, G., & Rienits, K. G. (1966). The oxidation of gentisaldehyde by nicotinamide-adenine dinucleotide-specific, aromatic aldehyde dehydrogenase from rabbit liver. Biochimica et Biophysica Acta, 118, 285–298.
Rutkowski, B., Slominska, E., Szolkiewicz, M., et al. (2003). N-methyl-2-pyridone-5-carboxamide: a novel urine toxin? Kidney International, 63, S19–S21.
Salek, R. M., Maguire, M. L., Bentley, E., et al. (2007). A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat and human. Physiological Genomics, 29, 99–108.
Seiler, N. (2004). Catabolism of polyamines. Amino Acids, 26, 217–233.
Seiler, N., Knodgen, B., & Haegele, K. (1982). N-(3-aminopropyl)pyrrolidin-2-one, a product of spermidine catabolism in vivo. Biochemical Journal, 208, 189–197.
Sigruener, A., Buechler, C., Orso, E., et al. (2007). Human aldehyde oxidase 1 interacts with ATP-binding cassette transporter-1 and modulates its activity in hepatocytes. Hormone and Metabolic Research, 39, 781–789.
Simmonds, H. A., Reitter, S., & Nishino, T. (1995). Hereditary xanthinuria. In C. R. Scriver, A. L. Beaudet, W. S. Sly, et al. (Eds.), The metabolic and molecular bases of inherited diseases (vol 2) (pp. 1781–1797). New York: McGraw-Hill, Inc.
Smith, M. A., Marinaki, A. M., Arenas, M., et al. (2009). Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Alimentary Pharmacology & Therapeutics, 30, 375–384.
Vorbach, C., Harrison, R., & Capecchi, M. R. (2003). Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends in Immunology, 24, 512–517.
Vorbach, C., Scriven, A., & Capecchi, M. R. (2002). The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. Genes & Development, 16, 3223–3235.
Weigert, J., Neumeier, M., Bauer, S., et al. (2008). Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3–L1 cells impairs adipogenesis and adiponectin release. FEBS Letters, 582, 2965–2972.
Zhou, S.-S., Li, D., Sun, W.-P., et al. (2009). Nicotinamide overload may play a role in the development of type 2 diabetes. World Journal of Gastroenterology, 15, 5674–5684.
Acknowledgments
We thank Scottish Life Sciences Alliance for funding scholarship of GB and acquisition of the Exactive mass spectrometer. Thanks are due to the referring physicians Drs. Renate Yakobov, Halil Heib and Dganit Dinour.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Peretz, H., Watson, D.G., Blackburn, G. et al. Urine metabolomics reveals novel physiologic functions of human aldehyde oxidase and provides biomarkers for typing xanthinuria. Metabolomics 8, 951–959 (2012). https://doi.org/10.1007/s11306-011-0391-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11306-011-0391-3